Studio the economically justifiable price in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy
We are very pleased to share a new publication of which OMAKASE is a co-author t [...]
Feasibility study to characterize price and reimbursement decision-making criteria for the inclusion of new drugs in the Spanish National Health System
We are very pleased to share the first study characterizing the criteria of the [...]
The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis
Omakase Consulting continues its focus and work on contributing to the generatio [...]
New publication about the incidence and management of patients with methotrexate delayed elimination
We are very pleased to share a new publication of which OMAKASE is a coauthor: a [...]
New publication about the socio-economic burden on patients, and their caregivers, suffering from severe thrombocytopenia associated with chronic liver disease (CLD) who undergo invasive procedures in Spain
We are pleased to share a new publication of which OMAKASE is a co-author on a r [...]
New publication in EC Gastroenterology and Digestive System
We are very pleased to share a new publication of which OMAKASE is a co-author t [...]
New publication about the treatment of focal-onset seizures (FOS) in patients with drug resistant epilepsy (DRE) in Spain
We are very pleased to share a new publication of which OMAKASE is a co-author t [...]
New publication about the treatment of triple-class refractory multiple myeloma in Spain
We are very pleased to share the latest publication for which OMAKASE is a coaut [...]
New evidence about risk factors of infections in adults due to carbapenem-resistant Pseudomonas aeruginosa or Acinetobacter baumannii in Spain
We are proud to publish with national experts in infectious diseases and microbi [...]
Clinical benefit, health priorities and economic evaluation lessons learnt with COVID-19 vaccine
Letter from Dr. Xavier Badia, EDS Director. [...]